

Proposal for a Regulation of the European Parliament and of the Council on Medicated Feed

Wolfgang Trunk DG SANCO - Animal Nutrition





Why a revision?

- Current Directive 90/167/EEC from 1990 has been established **before the creation of the internal market** and it has **never been adapted** in substance.

- The national transposition of this legal instrument has given freedom to Member States regarding interpretation and implementation of the legal provisions, but this **flexibility has contributed to some problems**.

- Need for a **holistic approach at EU level** to address **antimicrobial resistance** (AMR).


=> project launched 2008 - external report - IA







Upstream-downstream integration of MF





- 1. PROCEDURAL ISSUES AND CONSULTATION OF INTERESTED PARTIES
- 2. PROBLEM DEFINITION
- 3. OBJECTIVES
- 4. POLICY OPTIONS
- 5. ANALYSIS OF IMPACTS
- 6. COMPARING THE OPTIONS
- 7. MONITORING AND EVALUATION







General – strategic

(1) the smooth functioning of a competitive and innovative internal market
(2) ensuring a high level of protection of animal and public health.
Specific – operational

1. Overcome the zero-tolerance for unavoidable **carry-over** of VMP

2.Make MF available to farmers and pet owners at a **competitive price**

3.Curb **AMR-risk** from residual and sub-therapeutic administration of antimicrobials

4. Improve animal health by precise dosage of oral VMPs

5. Remove **barriers** for innovative, "novel" MF





Reasons for EU action

- 1. Protection of public health => competence given to EU by the Treaty. With respect to the AMR national efforts either contain an explicit call for EUaction or they implicitly hint that EU-action would be sensible
 - + VMP IA and "AMR 5Y action plan": holistic EU-Action
 - + Resolution of the European Parliament
 - + Council conclusions (Doc 10582/12)
- 2. Directive 90/167 was based on Art 43 TFEU (implementing CAP). Evidence that the existing provisions do not create a level playing field for EU agriculture nor assure a functioning internal market.
- => Choice for a Regulation as legal instrument
 => Articles 43 and 168(4)(b) as legal base (same as e.g. feed marketing)





Problems addressed (1)

1: Imprecise dosage of VMPs + preventive costs for MF production in some MS - Barriers to intra EU trade of MF

➤Manufacturing obligations including storing, transporting and placing on the market MF and IPs (art 3+4)

- adapted from feed hygiene regulation 183/2005, HACCP
- details laid down in Annex I

Incorporation (art 6)!
COM may ... establish criteria for the of the VMP into the MF

➤ Anticipated production: MF ... manufactured and stored before the prescription ... is issued (except on farm mixers and cascade)

➤Approval of FBOs manufacturing, storing, transporting or placing on the market MF and IPs by CAs (art 12+13)





Common rules cont

MF ... shall only be manufactured from VMPs authorised for the purpose of the manufacture of MF.

- Parameters for incorporation in Annex II (inclusion rates / mobile and on farm mixers !)
- Labelling (art 9): synthesis from feed and VMP provisions (annex III) tolerances (technological and analytical!) for deviation labelling-official controls: annex IV



Problems addressed (2)

2: Residues of VMPs in feed – Misuse of AMs –

Risk for the development of AMR

➤ Carry-over limits for VMP in non-target feed:

- *starting point*: 1% for antimicrobial active substances 3% for other VMPs
- to be revised based on scientific risk assessment (substance based)

➤no preventive use of MF with AMs

➤more restrictive rules for prescribing and handling MF with AMs







3: Limited market access of MF for pets

- >Establishment of distributors (*approval*) and anticipated production
- Specific provisions for labelling of medicated pet food
- ➤Specific provisions for prescription and use of medicated pet food





Thank you!

For more information on the revision of the legislation on medicated feed: http://ec.europa.eu/food/food/animalnutrition/labelling/medicated_fe ed_en.htm

